Print this page
-
A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects with FR alpha-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Protocol: 102502Principal Investigator:
- Aliza Leiser
Applicable Disease Sites: Ovary -
A Phase III Trial of One vs. Two Years of Maintenance Olaparib, with or Without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy.
Protocol: 102504Principal Investigator:
- Aliza Leiser
Applicable Disease Sites: Ovary -
A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6.
Protocol: 102503Principal Investigator:
- Aliza Leiser
Applicable Disease Sites: Ovary -
A Phase III Trial of One vs. Two Years of Maintenance Olaparib, with or Without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy.
Protocol: 102504Principal Investigator:
- Aliza Leiser
Applicable Disease Sites: Ovary -
A Randomized Phase III Trial of Carboplatin, Paclitaxel, Pembrolizumab versus Carboplatin, Paclitaxel, Bevacizumab versus Carboplatin, Paclitaxel, Pembrolizumab, Bevacizumab In The Treatment of pMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer.
Protocol: 102601Principal Investigator:
- Eugenia Girda
Applicable Disease Sites: Other Female Genital -
A Randomized Phase III Trial of Carboplatin, Paclitaxel, Pembrolizumab versus Carboplatin, Paclitaxel, Bevacizumab versus Carboplatin, Paclitaxel, Pembrolizumab, Bevacizumab In The Treatment of pMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer.
Protocol: 102601Principal Investigator:
- Eugenia Girda
Applicable Disease Sites: Other Female Genital -
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors.
Protocol: 111702Principal Investigator:
- Nehal Parikh
Applicable Disease Sites: Any Site
Ovary
Prostate -
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors.
Protocol: 111702Principal Investigator:
- Nehal Parikh
Applicable Disease Sites: Any Site
Ovary
Prostate -
A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors.
Protocol: 111904Principal Investigator:
- Nehal Parikh
Applicable Disease Sites: Other Female Genital
Other Male Genital -
A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors.
Protocol: 111904Principal Investigator:
- Nehal Parikh
Applicable Disease Sites: Other Female Genital
Other Male Genital -
Personalized Oncology Promoting Equity for Black Lives (PROPEL).
Protocol: 132309Principal Investigator:
- Anita Y Kinney
Applicable Disease Sites: Breast
Colon
Corpus Uteri
Ovary
Pancreas
Prostate -
ACCESS-PC: Advancing Care Coordination to Enhance Shared Care for Complex Survivors in Primary Care
Protocol: 132402Applicable Disease Sites: Breast
Corpus Uteri
Prostate
Urinary Bladder -
Personalized Oncology Promoting Equity for Black Lives (PROPEL).
Protocol: 132309Principal Investigator:
- Anita Y Kinney
Applicable Disease Sites: Breast
Colon
Corpus Uteri
Ovary
Pancreas
Prostate -
ACCESS-PC: Advancing Care Coordination to Enhance Shared Care for Complex Survivors in Primary Care
Protocol: 132402Applicable Disease Sites: Breast
Corpus Uteri
Prostate
Urinary Bladder -
A Feasibility Study of E7 TCR-T Cell Induction Therapy for Locoregionally Advanced HPV-Associated Cancers.
Protocol: 192104Principal Investigator:
- Christian Hinrichs
Applicable Disease Sites: Breast
Cervix
Lip, Oral Cavity and Pharynx
Other Female Genital
Other Male Genital
Stomach -
A Feasibility Study of E7 TCR-T Cell Induction Therapy for Locoregionally Advanced HPV-Associated Cancers.
Protocol: 192104Principal Investigator:
- Christian Hinrichs
Applicable Disease Sites: Breast
Cervix
Lip, Oral Cavity and Pharynx
Other Female Genital
Other Male Genital
Stomach